Litcius/Paper detail

Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab

Andrea Bacigalupo, Emanuele Angelucci, Anna Maria Raiola, Riccardo Varaldo, Carmen Di Grazia, Francesca Gualandi, E. Benedetti, Antonio M. Risitano, Maurizio Musso, Francesco Zallio, Fabio Ciceri, Patrizia Chiusolo, Simona Sica, Alessandro Rambaldi, Francesca Bonifazi, Matteo Parma, Massimo Martino, Francesco Onida, Anna Paola Iori, Carmine Selleri, Carlo Borghero, Alice Bertaina, Lucia Prezioso, Mattia Algeri, Franco Locatelli

2020Bone Marrow Transplantation31 citationsDOI

Topics & Concepts

MedicineInternal medicineProspective cohort studyGraft-versus-host diseaseGastroenterologyAdverse effectImmunologyMonoclonalRefractory (planetary science)Monoclonal antibodyDiseaseAntibodyPhysicsAstrobiologyHematopoietic Stem Cell TransplantationCAR-T cell therapy researchImmunotherapy and Immune Responses
Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab | Litcius